ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MXCT Maxcyte Inc

342.50
-2.50 (-0.72%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -0.72% 342.50 335.00 350.00 345.00 342.50 345.00 24,274 16:17:54
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 44.26M -23.57M -0.2277 -18.75 441.96M

MaxCyte, Inc. Disclosure of Remuneration for Non-Audit Services (9790C)

22/10/2020 6:22pm

UK Regulatory


Maxcyte (LSE:MXCT)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Maxcyte Charts.

TIDMMXCT TIDMTTM

RNS Number : 9790C

MaxCyte, Inc.

22 October 2020

Disclosure of Remuneration for Non-Audit Services

Gaithersburg, Maryland - 22 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announces an update to its previous disclosure of remuneration for audit-related services.

The Company previously disclosed on 14 October 2020 that the remuneration of the Company's auditors, Cohn Rezhnick LLC, for services relating to the 2019 financial year, amounted to approximately $137,000.

In order to further assist investors in considering the resolutions proposed ahead of the Company AGM, MaxCyte advises that these fees consisted of $119,000 for audit services and $18,000 for tax services, with no further costs incurred for any other services.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .

###

Contacts:

 
 MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Amanda Murphy, Chief Financial Officer                             +1 301-944-1660 
 Nominated Adviser and Joint Corporate 
  Broker 
  Panmure Gordon 
  Emma Earl 
  Freddy Crossley 
  Corporate Broking 
  Rupert Dearden                                                       +44 (0)20 7886 2500 
 Joint Corporate Broker 
  Numis Securities Limited 
  James Black 
  Duncan Monteith                                                      +44 (0)20 7260 1000 
 
   Financial PR Adviser                                                +44 (0)203 709 5700 
   Consilium Strategic Communications                                  maxcyte@consilium-com 
   Mary-Jane Elliott 
   Chris Welsh 
 
   -------------------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKKBBBOBDDDKB

(END) Dow Jones Newswires

October 22, 2020 13:22 ET (17:22 GMT)

1 Year Maxcyte Chart

1 Year Maxcyte Chart

1 Month Maxcyte Chart

1 Month Maxcyte Chart

Your Recent History

Delayed Upgrade Clock